Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Requirements
  • ‘Skinny Labeling’
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

TRENDING TOPICS:

  • Medicaid Work Requirements
  • 'Skinny Labeling'
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Jun 8 2023

Full Issue

Chemo Drug Shortage Is Impacting Treatments Across The US

News outlets report on worsening shortages of some common cancer treatments, which are forcing doctors to switch medications and delay care. More than 90% of large cancer centers are reporting chemo drug shortages. Also in the news: retail pharmacies, Astellas Pharma, GSK, and more.

AP: Cancer Centers Say US Chemotherapy Shortage Is Leading To Treatment Complications 

A growing shortage of common cancer treatments is forcing doctors to switch medications and delaying some care, prominent U.S. cancer centers say. The National Comprehensive Cancer Network said Wednesday that nearly all the centers it surveyed late last month were dealing with shortages of carboplatin and cisplatin, a pair of drugs used to treat a range of cancers. Some are no longer able to treat patients receiving carboplatin at the intended dose or schedule. (Murphy, 6/7)

CNN: More Than 90% Of Large US Cancer Centers Report Shortage Of Life-Saving Chemotherapy Drugs In New Survey 

Among some of the nation’s largest cancer centers, more than 90% have reported being directly affected by the current shortage of chemotherapy drugs in the United States, according to a new survey. The survey results, released Wednesday by the National Comprehensive Cancer Network, show that among 27 cancer centers across the country, the majority – 93% – have reported experiencing a shortage of the chemotherapy medication carboplatin, and 70% reported a similar shortage of the drug cisplatin. Carboplatin and cisplatin are used in combination to cure many types of cancer. (Howard, 6/7)

In other pharmaceutical and biotech news —

Axios: Retail Pharmacies Push To Save Role — And Payments — As Providers

Pharmacies that carved out new lines of business during the pandemic are pushing to expand their reach amid a broader effort to rethink the health care consumer experience. Pharmacies got paid to deliver vaccines, tests, and treatments for COVID during the pandemic. The experience primed consumers to expect the kind of on-demand health access retail pharmacies offer, executives say. (Reed, 6/8)

Stat: After Gene Therapy Deaths, Astellas Tries Potentially Safer Approach

Astellas Pharma said Thursday it will license and develop a new gene therapy for a devastating muscle disorder, after four boys died in a clinical trial testing an earlier treatment. The hope is that the new therapy will allow researchers to treat the disease, known as X-linked myotubular myopathy, or XLMTM, with much lower doses of the viruses used to shuttle genes into patients’ cells. (Mast, 6/8)

Stat: After Missing Vaccine Glory In Pandemic, GSK Aims For Other Diseases

GSK has been developing vaccines under one corporate guise or another for 140 years, ever since a rural Pennsylvania doctor started pumping smallpox shots out of a converted chicken house in 1882, but the company may be most known today for the vaccine it didn’t build. The British pharma elected not to develop its own Covid shot. (Mast, 6/7)

Stat: Akili Interactive Releases Video Game Treatment For Adult ADHD

Following positive top-line data released in May, Akili Interactive announced it will release its video game treatment for attention deficit hyperactivity disorder to adults who want to use it. (Aguilar, 6/7)

Indianapolis Star: IU Research Center Takes New Step In Breast Cancer Research - Accepting Samples From Men

Although Eric Hayes is a man, he is all too familiar with breast cancer, often considered a woman’s problem. His mother and one of his sisters died from the disease. Three other sisters were diagnosed and had double mastectomies within a space of three years. And, 15 years ago his wife Lisa was diagnosed with breast cancer and subsequently treated successfully. (6/8)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF